Uploaded May 2026 | Updated September 2026, 2 weeks ago
When Jill was diagnosed with non-small cell lung cancer (NSCLC), she had already lost both parents to the disease — her father at 41 and her mother at 54. Today, 17 years later, she's living proof of what advances in biomarker testing and targeted therapy can do. In this powerful conversation with Dr. Eric Singhi of MD Anderson Cancer Center, Jill shares her firsthand experience navigating an NSCLC diagnosis, explains why waiting for biomarker results before starting treatment is critical, and breaks down what driver mutations and next-generation sequencing (NGS) mean for patients.
Thank you, Jill F and Dr, Eric Singhi, for joining us for this conversation.
Thank you to AbbVie for its support of our patient story. The Patient Story retains full editorial control over all content.
#cancerpatient #cancersurvivor #patientstories #thepatientstory #cancertreatment #cancerprevention #cancersymptoms
The Patient Story:
The Patient Story is led by a dedicated team of medical, editorial, and video experts, committed to authentically portraying the cancer patient experience. Sharing your story holds transformative power, culturally and personally. We handle each narrative with utmost care, compassion, and scientific rigor.
Our editorial process adheres to the highest journalistic standards, ensuring medically researched, vetted, and fact-checked content. Backed by experienced medical professionals, we offer insights into the latest medical advancements.
Beyond patient narratives, we provide comprehensive coverage of cancer news and medical resources. From symptoms to clinical trials, insurance, finances, and support groups, we offer guidance in a humanized manner.
Join Our Community:
Sign up for our FREE website: thepatientstory.com
Facebook: facebook.com/thepatientstory
Instagram: instagram.com/thepatientstory
Twitter: twitter.com/Patient_Story
TikTok: tiktok.com/@patientstory
When Jill was diagnosed with non-small cell lung cancer (NSCLC), she had already lost both parents to the disease — her father at 41 and her mother at 54. Today, 17 years later, she's living proof of what advances in biomarker testing and targeted therapy can do. In this powerful conversation with Dr. Eric Singhi of MD Anderson Cancer Center, Jill shares her firsthand experience navigating an NSCLC diagnosis, explains why waiting for biomarker results before starting treatment is critical, and breaks down what driver mutations and next-generation sequencing (NGS) mean for patients.
Thank you, Jill F and Dr, Eric Singhi, for joining us for this conversation.
Thank you to AbbVie for its support of our patient story. The Patient Story retains full editorial control over all content.
#cancerpatient #cancersurvivor #patientstories #thepatientstory #cancertreatment #cancerprevention #cancersymptoms
The Patient Story:
The Patient Story is led by a dedicated team of medical, editorial, and video experts, committed to authentically portraying the cancer patient experience. Sharing your story holds transformative power, culturally and personally. We handle each narrative with utmost care, compassion, and scientific rigor.
Our editorial process adheres to the highest journalistic standards, ensuring medically researched, vetted, and fact-checked content. Backed by experienced medical professionals, we offer insights into the latest medical advancements.
Beyond patient narratives, we provide comprehensive coverage of cancer news and medical resources. From symptoms to clinical trials, insurance, finances, and support groups, we offer guidance in a humanized manner.
Join Our Community:
Sign up for our FREE website: thepatientstory.com
Facebook: facebook.com/thepatientstory
Instagram: instagram.com/thepatientstory
Twitter: twitter.com/Patient_Story
TikTok: tiktok.com/@patientstory
